https://www.selleckchem.com/products/wst-8.html
Median follow-up was 70.5 (range 7.6-88.9) months. The proportion of grade≥2 late adverse reactions within 3years was 4.3% (90% confidence interval 2.5-6.7%). Grade 2 early adverse events occurred in 38 (12.4%); none had grade 3/4. Five-year overall survival, disease-free survival and ipsilateral breast relapse-free survival were 98.7, 95.4 and 98.0%, respectively. Of the 304 evaluable patients, 29 (9.5%; 95% confidence interval 6.5-13.4%) had grade 2/3 late adverse reactions; none had grade 4/5. At 5years, 70/289 (24.2%) showed any worse
Like
Comment
Share
